Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy
Received Date : 29 Jun 2022
Accepted Date : 24 Oct 2022
Available Online : 07 Nov 2022
Doi: 10.37047/jos.2022-92230 - Article's Language: EN
J Oncol Sci. 2022;8(3):143-7
This is an open access article under the CC BY-NC-ND license
Objective: Surgery followed by chemotherapy with or without radiotherapy and perioperative chemotherapy represents the standard treatment modality in locally advanced gastric cancer patients. Adjuvant radiotherapy has been shown to have no benefits in these patients, especially those undergoing D2 dissection without neoadjuvant treatment. The goal of our study was to identify the prognostic factors associated with adjuvant treatments, particularly radiotherapy. Material and Methods: We evaluated the clinical, laboratory, and histological features and survival in locally advanced gastric cancer patients who underwent upfront gastric resection without neoadjuvant therapy and were subsequently treated with adjuvant chemotherapy comprising capecitabine-oxaliplatin. Parameters with significant p-values in univariate analysis were included in multivariate Cox regression analysis. Results: A total of 56 patients were included, and the median followup period was 33.2 months. The mean age was 61.23±8.89 years. The median disease-free survival (DFS) was 37.80 months (95% confidence interval: 22.30-53.30). The 5-year DFS and overall survival (OS) rates were 43.4% and 60.8%, respectively. In univariate analysis, lymph node involvement, diffuse histology, presence of lymphovascular invasion, positive surgical margin, presence of perineural invasion, absence of radiotherapy, and high lactate dehydrogenase (LDH) levels were found to be associated with shorter DFS and OS. In multivariate Cox regression analysis, diffuse histology, absence of radiotherapy, and high LDH levels were found to be associated with shorter DFS and OS. Conclusion: The long-term survival rates in our study were encouraging. Inflammatory markers, tumor histology, and radiotherapy might have prognostic value in identifying high-risk patients who could benefit from intensive therapy.
  1. Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239-248. [Crossref]  [PubMed]  [PMC] 
  2. GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):42-54. [PubMed]  [PMC] 
  3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. [Crossref]  [PubMed] 
  4. Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268-273. [Crossref]  [PubMed] 
  5. Hermanek P, Wittekind C. News of TNM and its use for classification of gastric cancer. World J Surg. 1995;19(4):491-495. [Crossref]  [PubMed] 
  6. Bu Z, Zheng Z, Li Z, et al. Lymphatic vascular invasion is an independent correlated factor for lymph node metastasis and the prognosis of resectable T2 gastric cancer patients. Tumour Biol. 2013;34(2):1005-1012. [Crossref]  [PubMed] 
  7. Cats A, Jansen EPM, van Grieken NCT, et al; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616-628. [PubMed] 
  8. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327-2333. [Crossref]  [PubMed]  [PMC] 
  9. Noh SH, Park SR, Yang HK, et al; CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389-1396. [Crossref]  [PubMed] 
  10. Li P, He HQ, Zhu CM, et al. The prognostic significance of lymphovascular invasion in patients with resectable gastric cancer: a large retrospective study from Southern China. BMC Cancer. 2015;15:370. [Crossref]  [PubMed]  [PMC] 
  11. del Casar JM, Corte MD, Alvarez A, et al. Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance. J Cancer Res Clin Oncol. 2008;134(2):153-161. [Crossref]  [PubMed] 
  12. Yaprak G, Tataroglu D, Dogan B, Pekyurek M. Prognostic factors for survival in patients with gastric cancer: Single-centre experience. North Clin Istanb. 2019;7(2):146-152. [PubMed]  [PMC] 
  13. Woo JW, Ryu KW, Park JY, et al. Prognostic impact of microscopic tumor involved resection margin in advanced gastric cancer patients after gastric resection. World J Surg. 2014;38(2):439-446. [Crossref]  [PubMed] 
  14. Bickenbach KA, Gonen M, Strong V, Brennan MF, Coit DG. Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol. 2013;20(8):2663-2668. [Crossref]  [PubMed] 
  15. Wang SY, Yeh CN, Lee HL, et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol. 2009;16(10):2738-2743. [Crossref]  [PubMed] 
  16. Becker K, Langer R, Reim D, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253(5):934-939. [Crossref]  [PubMed] 
  17. Liu GY, Liu KH, Zhang Y, et al. Alterations of tumor-related genes do not exactly match the histopathological grade in gastric adenocarcinomas. World J Gastroenterol. 2010;16(9):1129-1137. [Crossref]  [PubMed]  [PMC] 
  18. Becker REN, Meyer AR, Brant A, et al. Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2021;79(3):364-371. [PubMed] 
  19. Coburn NG, Swallow CJ, Kiss A, Law C. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer. 2006;107(9):2143-2151. [Crossref]  [PubMed] 
  20. de Manzoni G, Verlato G, di Leo A, et al. Perigastric lymph node metastases in gastric cancer: comparison of different staging systems. Gastric Cancer. 1999;2(4):201-205. [Crossref]  [PubMed] 
  21. Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY, Shen KH. Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology. 2002;49(45):874-877. [PubMed] 
  22. Sun X, Sun Z, Zhu Z, et al. Clinicopathological significance and prognostic value of lactate dehydrogenase A expression in gastric cancer patients. PLoS One. 2014;9(3):e91068. [Crossref]  [PubMed]  [PMC] 
  23. Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol. 2015;54(7):961-970. [Crossref]  [PubMed]